Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD 0360324 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PD 0360324 | DRUG | 3 doses of PD 0360324 (Dose level 1) administered over 12 weeks |
| Placebo | DRUG | 3 doses of Placebo administered over 12 weeks |
Inclusion Criteria: * Diagnosis of RA for at least 6 months based upon the American College of Rheumatology (ACR) 1987 Revised Criteria. * Must have been treated with methotrexate (≥7.5 mg/week to ≤25 mg/week) for at least 16 weeks immediately prior to enrollment. The dose of methotrexate must be s...
PD 0360324 is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is being studied in combination with methotrexate in patients with this condition. The drug is currently in Phase 1 clinical development and is not yet approved for any use.
PD 0360324 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for rheumatoid arthritis.
PD 0360324 is in Phase 1 clinical development. It is an investigational drug being studied for rheumatoid arthritis and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed.
PD 0360324 has one completed clinical trial, NCT00550355, a dose-escalating multiple dose study of PD-0360324 in combination with methotrexate in patients with rheumatoid arthritis. The trial enrolled 78 participants across the United States, Argentina, Bulgaria, Czechia, Mexico, Poland, Slovakia, and Spain.
PD 0360324 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for rheumatoid arthritis. The drug has completed one early-stage clinical trial, but it remains under study and has not been approved for any medical use.